
|Articles|August 1, 2003
Biochemotherapy Gets Thumb's Down
Author(s)Caroline Helwick
Chicago - The promise of biochemotherapy for stage IV malignant melanoma has not held up to scrutiny, and the value of this form of treatment seems nil, according to recent discouraging findings from major phase III clinical trials.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Q&A: How Clinicians Are Healing “Overdosed” Skin Damaged by Viral Trends
2
AEON's ABP-450 Achieves Critical Analytical Milestone, Demonstrating High Biosimilarity to BOTOX
3
Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years
4
Beyond Antibiotics: How Oral Denifanstat Could Reshape the Acne Pipeline
5



















